Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

Guerbet (0ELV)

Guerbet Sa
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0ELV
DateTimeSourceHeadlineSymbolCompany
23/07/202416:52UK RegulatoryGUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 juin 2024LSE:0ELVGuerbet Sa
18/03/202410:37UK RegulatoryGUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 29 février 2024LSE:0ELVGuerbet Sa
19/02/202416:46UK RegulatoryGUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 janvier 2024LSE:0ELVGuerbet Sa
11/12/202316:45PR Newswire (US)Guerbet announces marketing authorisation approval of Elucirem™ (Gadopiclenol) in the European UnionLSE:0ELVGuerbet Sa
21/09/202218:08PR Newswire (US)Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)LSE:0ELVGuerbet Sa
13/06/202207:30PR Newswire (US)Guerbet receives EMA acceptance of Elucirem™ as the Brand Name for GadopiclenolLSE:0ELVGuerbet Sa
07/03/202217:00PR Newswire (US)Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolizationLSE:0ELVGuerbet Sa
07/03/202217:00PR Newswire (US)Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolizationLSE:0ELVGuerbet Sa
 Showing the most relevant articles for your search:LSE:0ELV